Our initial target indications in clinical development are Clinical High Risk for Psychosis and patients suffering from Insomnia Disorder, using our CBD micelle formulation.
In addition, we are in pre-clinical development for General Anxiety Disorder (GAD), Restless Legs Syndrome (RLS) and Post-Traumatic Stress Disorder (PTSD).
Having completed pre-clinical & formulation work with the University of Toronto, we will go into Phase 2 A/B for Insomnia Disorder and Phase 3 for Clinically High Risk (CHR) for Psychosis, starting in 2023.
Why CBD as a lead molecule? - Efficacious, safe and ready for re-formulation
Efficacious for a range of indications
- CBD has a network of actions on many receptors, pathways and systems in the body, including the endocannabinoid system (one of the key homeostatic regulatory systems of the body)
- Potential for a wide range of indications:brain functioning, psychiatry, sleep, pain, mood, inflammation, oxidation and the immune system
- Millions of people are using CBD for sleep (although with sub-optimal formulation and dosing)
CBD has been shown to be neuroprotective and effective for treatment and prevention of psychosis
- CBD displays a markedly superior side-effect profile to existing medications, and it has been found to be safe